Gilde Healthcare
en nl de
  • Portefeuille
  • Team
  • Nieuws
  • Over ons
  • Contact

Nieuws 2020

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Follow @GildeHealthcare

Gilde Healthcare participates in €51M series A financing of Noema Pharma

1 december 2020 – €51 million to advance a pipeline of four clinical-stage product candidates in-licensed from Roche to treat orphan neurological disorders Highly experienced team leverages latest scientific discoveries in neuroscience Gilde Healthcare joins an international investor syndicate…

Gerelateerd aan: Noema Pharma

MercachemSyncom changes name to Symeres

19 november 2020 – Nijmegen (The Netherlands) – MercachemSyncom today announced that it will change its name and operate under the registered trade name of Symeres.   The new name reflects the strategic evolution of the company, with the growth of integrated drug discovery and development services,…

Gerelateerd aan: Symeres

Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

16 november 2020 – Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis Amsterdam, The Netherlands - Calypso Biotech, a company developing Interleukin-15-targeted biologics, today…

Gerelateerd aan: Calypso Biotech B.V.

Inari Medical Announces Presentation of Positive 30-Day Follow-Up Results from First Patients in Real World FLASH Registry

13 november 2020 – IRVINE, Calif. — (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced follow-up results of the first 230…

Gerelateerd aan: Inari Medical, Inc.

AM-PHARMA Announces Enrollment of the First Patient in REVIVAL Phase III Pivotal Trial in Patients with Sepsis-Associated Acute Kidney Injury

12 november 2020 – Trial to confirm potential of AM-Pharma’s recombinant alkaline phosphatase to reduce mortality, as demonstrated in the Phase II STOP-AKI study Target enrolment of up to 1,600 SA-AKI patients at ICUs in Europe, United Kingdom and North America Utrecht, The Netherlands – AM-Pharma…

Gerelateerd aan: AM Pharma

Drug discovery CRO MercachemSyncom adds biology services through acquisition

9 november 2020 – Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, today announced that it has acquired Admescope Ltd., a provider of ADME-Tox services, based in Oulu (Finland) and Södertälje…

Gerelateerd aan: Symeres

Eargo, Inc. announces pricing of Initial Public Offering

16 oktober 2020 – San Jose (CA, US) – Eargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced today the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of $18.00 per share.…

Gerelateerd aan: Eargo, Inc.

Nyxoah raises up to €85 million (US$100M) in successful initial public offering

17 september 2020 – NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, SOUTH AFRICA, CANADA, JAPAN Utrecht (The Netherlands) – Gilde Healthcare company Nyxoah (the “Company”) a health-technology company focused…

Gerelateerd aan: Nyxoah

Lava Therapeutics announces $83 million series C financing to advance novel gamma-delta T cell engager programs

17 september 2020 – Utrecht (The Netherlands) and Philadelphia – Gilde Healthcare company Lava Therapeutics announced the closing of an oversubscribed $83 million (€71 million) Series C financing to fund the advancement of its pipeline and platform. The financing was co-led by new investors Novo Ventures…

Gerelateerd aan: Lava Therapeutics

Nyxoah announces intention to launch an Initial Public Offering on Euronext Brussels

27 augustus 2020 – Mont-Saint-Guibert (Belgium) and Utrecht (The Netherlands) – Nyxoah S.A. (“Nyxoah” or the “Company”) a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions, today announces its…

Gerelateerd aan: Nyxoah

Acacia Pharma commercially launches BARHEMSYS® in the US for the treatment of prevention of postoperative nausea & vomiting

24 augustus 2020 – Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures,…

Gerelateerd aan: Acacia Pharma

Acacia Pharma raises €25M to launch BARHEMSYS® and BYFAVO™ in the US

14 augustus 2020 – Cambridge (UK) and Indianapolis (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures,…

Gerelateerd aan: Acacia Pharma

Lumeon raises $30M to fuel growth in the US

11 augustus 2020 – Boston (Massachusetts, US) and Utrecht (The Netherlands) – Lumeon, the leader in care pathway orchestration, today announced that it has closed $30M in Series D funding led by new investors Optum Ventures and Endeavour Vision, with participation from current investors Gilde Healthcare,…

Gerelateerd aan: Lumeon

LUMICKS enters collaboration with Glycostem to enhance NK cell-mediated immunotherapy via avidity analyses

31 juli 2020 – Utrecht (The Netherlands) and Amsterdam (The Netherlands) – LUMICKS has entered into a collaboration with Glycostem Therapeutics, the Netherlands, to improve immunotherapeutic drug development. By quantifying binding strength between immune and cancer cells using the unique z-Movi®…

Gerelateerd aan: Lumicks B.V.

Gilde Healthcare Partners co-leads $71 million financing round in hearing aid manufacturer Eargo

30 juli 2020 – Utrecht (The Netherlands) and Boston (Massachusetts, US) – Eargo Inc. (San Jose, CA), a medical device company on a mission to improve the quality of life of people with hearing loss, today announced the closing of a $71 million equity financing, co-led by new investors Gilde Healthcare…

Gilde Healthcare leads $60 million growth financing round in healthtech scale-up Withings

29 juli 2020 – Paris (France) and Utrecht (The Netherlands) – Withings, an early pioneer of connected health devices , announced today that it raised a $60 million Series B funding round, co-led by Gilde Healthcare, Idinvest Partners and Bpifrance with additional support from BNP Paribas Developpement,…

CVRx® raises $50 million in new equity financing

8 juli 2020 – Utrecht (The Netherlands) and Boston (Massachusetts, US) – CVRx, Inc., a private medical device company commercialising a novel technology that treats patients suffering from chronic heart failure ("HF") and resistant hypertension, announced today that it raised $50 million to close…

Gerelateerd aan: CVRx

CVRx® announces publication of BeAt-HF clinical study results in the journal of the American College of Cardiology

3 juli 2020 – MINNEAPOLIS (US) – CVRx, Inc., a private medical device company, announced today that its BeAT-HF phase III randomized clinical trial results were published in the Journal of the American College of Cardiology (“JACC”). Results from the trial were used to obtain Premarket Approval…

Gerelateerd aan: CVRx

Acacia Pharma announces US FDA approval of BYFAVO™ (remimazolam) for procedural sedation

3 juli 2020 – CAMBRIDGE (UK), INDIANAPOLIS (US) – Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or…

Gerelateerd aan: Acacia Pharma

Gilde Healthcare leads $39 million in Series B financing in Big Health

18 juni 2020 – SAN FRANCISCO, CA (US), UTRECHT (THE NETHERLANDS) – Big Health, the global leader in digital therapeutics dedicated to helping millions back to good mental health, today announced it has raised $39 million in a Series B financing, led by Gilde Healthcare and joined by new investors…

Inari Medical closes upsized initial public offering

27 mei 2020 – IRVINE, CALIFORNIA – Inari Medical Inc. today announced the closing of its initial public offering on NASDAQ. Inari is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. The gross proceeds…

Gerelateerd aan: Inari Medical, Inc.

Lava Therapeutics announces collaboration with Johnson & Johnson to develop bi-specific gamma-delta T-cell engager therapeutics

15 mei 2020 – Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Dutch biopharmaceutical start-up Lava Therapeutics B.V., today announced that it has entered into a research and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson,…

Gerelateerd aan: Lava Therapeutics

Axonics Modulation Technologies raises $130 million via public offering

11 mei 2020 – Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that is commercializing novel implantable rechargeable sacral neuromodulation devices (r-SNM Systems) for the treatment of bladder and bowel…

Gerelateerd aan: Axonics Modulation Technologies

Vapotherm raises $87 million via public offering

11 mei 2020 – Utrecht (the Netherlands), Cambridge, Massachusetts (USA) – Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on the commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress,…

Gerelateerd aan: Vapotherm

Gilde Healthcare haalt €416 miljoen ($450 miljoen) op met venture en groeikapitaalfonds

31 maart 2020 – Utrecht (Nederland), Cambridge, Massachusetts (USA) – Gilde Healthcare kondigt vandaag de eerste en definitieve sluiting aan van Gilde Healthcare V, een venture en groeikapitaalfonds met een waarde van €416 miljoen ($450 miljoen). Het nieuwe fonds, dat was overtekend, richt zich op…

Respiratory company Vapotherm provides business update in response to COVID-19 pandemic

24 maart 2020 – New Hampshire (United States) – Vapotherm, Inc. (NYSE: VAPO), the Gilde Healthcare company focused on the commercialization of its proprietary Hi-VNI Technology products that are used to treat patients suffering from respiratory distress, today announced an update on their business…

Gerelateerd aan: Vapotherm

Acacia Pharma announces year and results and outlook 2020

3 maart 2020 – Cambridge (United Kingdom) and Indianapolis (United States) – Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery,…

Gerelateerd aan: Acacia Pharma

Acacia Pharma announces US FDA approval of BARHEMSYS® to treat PONV

27 februari 2020 – Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare company Acacia Pharma (EURONEXT: ACPH), a hospital pharmaceutical company focused on therapeutic solutions improving the care of patients undergoing significant treatments such as surgery, other invasive…

Gerelateerd aan: Acacia Pharma

Ablative Solutions Announces Publication of Data from the Peregrine Post-Market Study in the Journal of the American College of Cardiology: Cardiovascular Interventions

20 februari 2020 – Data Provide Preliminary Evidence of Efficacy of the Investigational Peregrine System Kit SAN JOSE, Calif. — Ablative Solutions, Inc., a company pioneering new approaches for the treatment of hypertension, today announced that positive six-month results from the Peregrine Post-Market…

Gerelateerd aan: Ablative Solutions

First patient dosed in pivotal phase 3 trial of SNF472 in calciphylaxis

13 februari 2020 – First patient dosed in phase 3 trial of SNF472 for the treatment of calcific uremic arteriolopathy (CUA) or calciphylaxis Palma, Spain and San Diego, USA – Sanifit, a clinical-stage biopharmaceutical company focused on developing treatments for calcification disorders, today announced…

Gerelateerd aan: Sanifit

Axonics® receives reimbursement approval in Germany for its Sacral Neuromodulation

4 februari 2020 – Irvine, CA (United States) – Gilde Healthcare portfolio company Axonics Modulation Technologies, Inc. (NASDAQ:AXNX), a medical technology company that has developed and is commercializing novel implantable rechargeable Sacral Neuromodulation (“SNM”) devices for the treatment of bladder…

Gerelateerd aan: Axonics Modulation Technologies

Acacia Pharma wins BEL Small Company of the Year Award 2019

24 januari 2020 – Cambridge (United Kingdom) and Indianapolis (United States) – Gilde Healthcare portfolio company Acacia Pharma Group plc (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, has been awarded BEL Small Company…

Gerelateerd aan: Acacia Pharma

Acacia Pharma signs strategic in-licensing and finance agreement with Cosmo Pharmaceuticals N.V.

10 januari 2020 – Acacia Pharma has in-licensed exclusive US rights to ultra-short-acting sedative, ByFavo™ (remimazolam) from Cosmo adding to its portfolio of near-market products Cosmo will make a €10 million equity investment in Acacia Pharma and provide a new €35 million loan facility to support…

Gerelateerd aan: Acacia Pharma

MercachemSyncom acquires the European operations of Alcami

9 januari 2020 – Utrecht (the Netherlands) – Gilde Healthcare portfolio company MercachemSyncom, the leading mid-sized European drug-discovery contract research organization, has announced that it has acquired Alcami’s European cGMP CMC drug substance development site, based in Weert, the Netherlands. The…

Gerelateerd aan: Symeres

Lava Therapeutics appoints immuno-oncology experts James Allison, Ph.D. and Padmanee Sharma, M.D., Ph.D. to advisory board

9 januari 2020 – Utrecht (the Netherlands) and Philadelphia (United States) – Gilde Healthcare company Lava Therapeutics (“LAVA”) announced that James P. Allison, Ph.D., a 2018 Nobel Prize recipient in Physiology or Medicine for his discovery of cancer therapy by inhibition of negative immune regulation,…

Gerelateerd aan: Lava Therapeutics

Gilde Healthcare

Gilde Healthcare

Gilde Healthcare is een gespecialiseerde Europese investeringsmaatschappij met €1.4 miljard ($1.5 miljard) onder beheer in twee aparte fondsstrategieën: venture & groeikapitaal en private equity. Gilde Healthcare's venture & groeikapitaalfonds participeert in medische technologie en nieuwe geneesmiddelen. De venture & groeibedrijven zijn gevestigd in Europa en Noord Amerika. Gilde Healthcare’s private equity fonds neemt deel in winstgevende Europese bedrijven met een primaire focus op de middenmarkt in Benelux en Duitstalige landen. Het private equity fonds is gericht op zorgverleners, toeleveranciers en producenten van medische producten en overige dienstverleners actief in de zorgsector.

Investeringsfilosofie

Gilde Healthcare investeert in snelgroeiende, innovatieve bedrijven die betere zorg tegen lagere kosten mogelijk maken.

  • Home
  • Portefeuille
  • Team
  • Nieuws
  • Contact
  • Imprint
  • Privacy Policy